Advertisement

Lung Transplantation for Pulmonary Arterial Hypertension

  • Helen Whitford
Chapter

Abstract

Pulmonary arterial hypertension constitutes a group of disorders with a common haemodynamic definition. There are a number of medical therapies available for these diseases, but a proportion of patients will not respond adequately and will require lung transplantation as the final therapy.Lung transplantation in this disease is extremely complex both in the timing or referral and listing for transplantation and in the peri-operative management. With careful decision making excellent long term results can be achieved.

References

  1. 1.
    Yusen RD, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-third adult lung and heart-lung transplant report-2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35(10):1170–84.CrossRefPubMedGoogle Scholar
  2. 2.
    Andersen KH, et al. Pulmonary hypertension as a risk factor of mortality after lung transplantation. Clin Transpl. 2016;30(4):357–64.CrossRefGoogle Scholar
  3. 3.
    Hoeper MM, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42–50.CrossRefPubMedGoogle Scholar
  4. 4.
    Galiè N, et al. ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015;37(1):67–119.CrossRefPubMedGoogle Scholar
  5. 5.
    Barst RJ, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296–301.CrossRefGoogle Scholar
  6. 6.
    Rubin LJ, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112(7):485–91.CrossRefPubMedGoogle Scholar
  7. 7.
    Sitbon O, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105–11.CrossRefGoogle Scholar
  8. 8.
    Reitz BA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med. 1982;306(10):557–64.CrossRefPubMedGoogle Scholar
  9. 9.
    Kramer MR, et al. Recovery of the right ventricle after single-lung transplantation in pulmonary hypertension. Am J Cardiol. 1994;73(7):494–500.CrossRefPubMedGoogle Scholar
  10. 10.
    Pielsticker EJ, Martinez FJ, Rubenfire M. Lung and heart-lung transplant practice patterns in pulmonary hypertension centers. J Heart Lung Transplant. 2001;20(12):1297–304.CrossRefPubMedGoogle Scholar
  11. 11.
    Olland A, et al. Should we perform bilateral-lung or heart-lung transplantation for patients with pulmonary hypertension? Interact Cardiovasc Thorac Surg. 2013;17(1):166–70.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Schaffer JM, et al. Transplantation for idiopathic pulmonary arterial hypertension: improvement in the lung allocation score era. Circulation. 2013;127(25):2503–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Levvey BJ, et al. Donation after circulatory determination of death lung transplantation for pulmonary arterial hypertension: passing the toughest test. Am J Transplant. 2015;15(12):3208–14.CrossRefPubMedGoogle Scholar
  14. 14.
    Weill D, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34(1):1–15.CrossRefPubMedGoogle Scholar
  15. 15.
    Kylhammar D, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2017.Google Scholar
  16. 16.
    Humbert M, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36(3):549–55.CrossRefPubMedGoogle Scholar
  17. 17.
    Benza RL, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164–72.CrossRefPubMedGoogle Scholar
  18. 18.
    Lantuejoul S, et al. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol. 2006;30(7):850–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Humbert M, et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1681–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Montani D, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore). 2008;87(4):220–33.CrossRefGoogle Scholar
  21. 21.
    Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J. 1958;2(5099):755–62.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Choong CK, et al. Repair of congenital heart lesions combined with lung transplantation for the treatment of severe pulmonary hypertension: a 13-year experience. J Thorac Cardiovasc Surg. 2005;129(3):661–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Waddell TK, et al. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant. 2002;21(7):731–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Galie N, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s syndrome. Drugs. 2008;68(8):1049–66.CrossRefPubMedGoogle Scholar
  25. 25.
    Avouac J, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 2010;37(11):2290–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Hachulla E, et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology (Oxford). 2009;48(3):304–8.CrossRefGoogle Scholar
  27. 27.
    Bernstein EJ, et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol. 2015;67(5):1314–22.CrossRefPubMedGoogle Scholar
  28. 28.
    Launay D, et al. Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. Presse Med. 2014;43(10 Pt 2):e345–63.CrossRefPubMedGoogle Scholar
  29. 29.
    Christie JD, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report—2008. J Heart Lung Transplant. 2008;27(9):957–69.CrossRefPubMedGoogle Scholar
  30. 30.
    Diamond JM, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2013;187(5):527–34.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Halldorsson AO, et al. Controlled reperfusion prevents pulmonary injury after 24 hours of lung preservation. Ann Thorac Surg. 1998;66(3):877–84; discussion 884-5.CrossRefPubMedGoogle Scholar
  32. 32.
    Tudorache I, et al. Lung transplantation for severe pulmonary hypertension—awake extracorporeal membrane oxygenation for postoperative left ventricular remodelling. Transplantation. 2015;99(2):451–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Fuehner T, et al. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med. 2012;185(7):763–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Pilkington SA, Taboada D, Martinez G. Pulmonary hypertension and its management in patients undergoing non-cardiac surgery. Anaesthesia. 2015;70(1):56–70.CrossRefPubMedGoogle Scholar
  35. 35.
    Ius F, et al. Lung transplantation on cardiopulmonary support: venoarterial extracorporeal membrane oxygenation outperformed cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2012;144(6):1510–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Akagi S, et al. High frequency of acute adverse cardiovascular events after lung transplantation in patients with pulmonary arterial hypertension receiving preoperative long-term intravenous prostacyclin. Int Heart J. 2017;58(4):557–61.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Respiratory MedicineThe Alfred HospitalMelbourneAustralia
  2. 2.Monash UniversityClaytonAustralia

Personalised recommendations